Nektar Therapeutics (NKTR) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $73.77 -1.59%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $40.85 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
- Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
- Bath & Body Works, Inc. (BBWI) Tops Q2 EPS by 38c, Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
